Claims
- 1. A process for the detection and characterization of psychoactive compounds in a neuronal tissue sample comprising:
a) measuring a combination of parameters from a set of baseline oscillations induced by contacting the neuronal tissue sample with an inducing agent, and from a set of resulting oscillations generated after contact of the neuronal tissue sample with a candidate sample composition; b) comparing said combination of parameters from the set of baseline oscillations and resulting oscillations; and c) detecting the presence or absence of a psychoactive compound in the candidate sample composition, and if a psychoactive compound is present, characterizing said psychoactive compound based upon the differences between said combination of parameters from the set of baseline oscillations and resulting oscillations.
- 2. The process of claim 1 wherein the step of characterizing identifies a compound class of which said psychoactive compound is a member.
- 3. The process of claim 2 further comprising the step of comparing relative differences between said identified compound class and one or more different psychoactive compound classes.
- 4. The process of claim 2 further comprising the step of distinguishing said psychoactive compound from other members of the compound class.
- 5. The process of claim 1 wherein said combination of parameters comprises frequency and power.
- 6. The process of claim 1 wherein the comparing step comprises comparing at least two parameters.
- 7. The process of claim 6 wherein said at least two parameters are frequency and power.
- 8. A method for the detection and characterization of a psychoactive compound in neuronal tissue comprising the steps of:
a) contacting an inducing agent with the neuronal tissue to produce a set of baseline oscillations in the neuronal tissue; b) contacting a candidate sample composition with the neuronal tissue to produce a set of resulting oscillations in the neuronal tissue; c) detecting a combination of parameters from said set of baseline and resulting oscillations; and d) comparing said combination of parameters from the set of baseline and resulting oscillations to detect and characterize said psychoactive compound in the candidate sample composition.
- 9. The method of claim 8 further comprising the step of removing the inducing agent from the neuronal tissue.
- 10. The method of claim 8 wherein said combination of parameters comprises frequency and power.
- 11. The method of claim 8 wherein said psychoactive compound is selected from the group consisting of AMPA antagonists, AMPA receptor modulators, antianxiety drugs, anticonvulsants, antidepressant drugs, antipsychotic drugs, benzodiazepines, central nervous system stimulants, dopaminergic agents, GABA antagonists, hypnotic drugs, and narcotic analgesics.
- 12. The method of claim 11 wherein said psychoactive compound comprises an AMPA antagonist.
- 13. The method of claim 12 wherein said AMPA antagonist is selected from the group consisting of CNQX, DNQX, GYKI 52466HCl, Joro spider toxin, 1-Naphthylacetyl spermine, NS257, and NBQX.
- 14. The method of claim 11 wherein said psychoactive compound comprises an AMPA receptor modulator.
- 15. The method of claim 14 wherein said AMPA receptor modulator comprises an ampakine.
- 16. The method of claim 15 wherein said AMPA receptor modulator is selected from the group consisting of CX516, CX546, CX554, CX614, and CX691.
- 17. The method of claim 11 wherein said psychoactive compound comprises a benzodiazepine.
- 18. The method of claim 17 wherein said benzodiazepine is selected from the group consisting of alprazolam, bromazepam, chlordiazepoxide, clorazepate, clotiazepam, diazepam, estazolam, etizolam, fludiazepam, flumazenil, flunitrazepam, flurazepam, flutoprazepam, hloxazolam, lorazepam, medazepam, nimetazepam, nitrazepam, oxazepam, oxazolam, rimazafone, temazepam, and trizolam.
- 19. The method of claim 17 wherein said benzodiazepine is selected from the group consisting of diazepam, chlordiazepoxide, flurazepam, and triazolam.
- 20. The method of claim 11 wherein said psychoactive compound comprises a GABA antagonist.
- 21. The method of claim 20 wherein said GABA antagonist is selected from the group consisting of bicuculline, β-hydrastine, picrotoxin, and SR-95531 (Gabazine).
- 22. The method of claim 21 wherein said GABA antagonist comprises bicuculline.
- 23. The method of claim 21 wherein said GABA antagonist comprises picrotoxin.
- 24. The method of claim 8 wherein the inducing agent for producing the set of baseline oscillations is a chemical compound.
- 25. The method of claim 24 wherein said chemical compound is selected from the group consisting of cholinergic agonists, cholinesterase inhibitors, and sympathetic agonists.
- 26. The method of claim 25 wherein said chemical compound comprises a cholinergic agonist.
- 27. The method of claim 26 wherein said cholinergic agonist is selected from the group consisting of acetylcholine, arechol, carbachol, methacholine, bethanechol, muscarine, and pilocarpine.
- 28. The method of claim 27 wherein said cholinergic agonist comprises carbachol.
- 29. The method of claim 25 wherein said chemical compound comprises a cholinesterase inhibitor.
- 30. The method of claim 29 wherein said cholinesterase inhibitor is selected from the group consisting of ambenonium, demecarium, diidopropyl-fluorophosphate, echothiophate, edrophonium, huperzine and huperzine analogs, neostigmine, physotigmine, and pyridostigmine.
- 31. The method of claim 30 wherein said cholinesterase inhibitor comprises physostigmine.
- 32. The method of claim 24 wherein said chemical compound selectively binds a muscarinic M1 receptor.
- 33. The method of claim 8 wherein the inducing agent is an electrical stimulation.
- 34. The method of claim 8 wherein the inducing agent is co-deposited neuronal tissue.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part application of U.S. application Ser. No. 09/602,629 filed Jun. 21, 2000, which is incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. NIA AG-00538 455365-29174 awarded by the National Institute of Health.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60140339 |
Jun 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09602629 |
Jun 2000 |
US |
Child |
10352629 |
Jan 2003 |
US |